Table 2.
Variable | Full Cohort | Matching | IPTW | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 |
---|---|---|---|---|---|---|---|---|
Age | 0.004 | −0.011 | −0.017 | 0.216 | 0.014 | 0.024 | 0.120 | −0.245 |
Female | −0.097 | −0.011 | 0.023 | 0.055 | 0.163 | −0.059 | 0.070 | −0.204 |
White race | −0.066 | 0.016 | −0.008 | −0.054 | −0.015 | 0.015 | −0.000 | −0.026 |
Black race | 0.077 | −0.030 | 0.020 | 0.063 | 0.061 | 0.023 | −0.018 | −0.046 |
Asian race | −0.044 | 0.021 | −0.022 | −0.110 | −0.036 | −0.004 | −0.054 | 0.153 |
Latino ethnicity | 0.013 | 0.045 | −0.014 | −0.019 | −0.220 | 0.004 | 0.187 | −0.010 |
Weight in kilograms | 0.023 | −0.010 | 0.019 | 0.325 | −0.128 | 0.046 | 0.084 | −0.153 |
End-stage liver disease | −0.039 | 0.006 | −0.021 | −0.174 | 0.129 | −0.121 | 0.063 | 0.013 |
End-stage renal disease requiring dialysis | −0.129 | 0.012 | −0.014 | −0.096 | 0.113 | 0.031 | −0.025 | −0.145 |
Structural lung disease | −0.112 | 0.042 | −0.014 | 0.033 | −0.041 | 0.116 | −0.029 | −0.148 |
Congestive heart failure (ejection fraction <45%) | −0.018 | 0.000 | −0.009 | 0.001 | −0.022 | 0.107 | −0.042 | −0.029 |
Diabetes | 0.049 | 0.003 | −0.016 | 0.026 | −0.037 | −0.002 | 0.076 | −0.021 |
Human immunodeficiency virus | 0.036 | 0.007 | −0.021 | −0.247 | −0.122 | 0.134 | 0.101 | −0.055 |
Chemotherapy within 6 months | 0.010 | 0.021 | −0.006 | −0.056 | −0.113 | 0.239 | 0.048 | −0.173 |
Absolute neutrophil count <500 cells/mL | −0.242 | 0.005 | 0.042 | 0.288 | −0.075 | −0.199 | 0.062 | * |
Immunomodulatory therapy or high-dose steroids within 30 days | 0.023 | 0.015 | −0.012 | −0.108 | −0.006 | 0.005 | 0.120 | −0.052 |
Solid organ transplant | 0.095 | −0.018 | −0.015 | −0.029 | −0.140 | 0.130 | −0.055 | 0.067 |
Hematopoietic stem cell transplant within 12 months | −0.182 | 0.007 | 0.030 | 0.136 | −0.001 | −0.204 | −0.055 | 0.085 |
Total days of antibiotic therapy | 0.229 | 0.023 | −0.027 | −0.104 | −0.028 | −0.004 | 0.102 | 0.138 |
Combination antibiotic therapy for >48 hours | −0.204 | 0.000 | −0.015 | −0.121 | −0.014 | 0.128 | −0.140 | 0.011 |
Respiratory source | −0.242 | −0.027 | −0.044 | −0.186 | 0.051 | −0.020 | 0.027 | * |
Skin and soft tissue source | −0.078 | 0.070 | −0.019 | −0.075 | −0.137 | 0.131 | 0.018 | 0.148 |
Urinary tract source | 0.343 | −0.030 | −0.021 | −0.098 | −0.069 | 0.093 | 0.066 | 0.045 |
Biliary source | 0.069 | 0.000 | 0.010 | 0.205 | −0.035 | 0.038 | −0.101 | −0.008 |
Intra-abdominal source | −0.107 | 0.030 | 0.004 | −0.018 | 0.068 | −0.127 | 0.086 | −0.068 |
Catheter-associated source | −0.162 | −0.017 | 0.022 | 0.185 | 0.053 | −0.100 | −0.101 | 0.027 |
Pitt bacteremia score on day 1 | −0.535 | 0.048 | 0.020 | −0.453 | −0.053 | 0.036 | 0.119 | −0.012 |
Intensive care unit on day 1 | −0.324 | 0.013 | 0.013 | −0.047 | −0.178 | 0.125 | −0.019 | −0.017 |
Citrobacter spp. | 0.060 | 0.049 | 0.058 | 0.198 | 0.128 | −0.011 | −0.088 | 0.086 |
Enterobacter spp. | −0.037 | 0.008 | 0.073 | 0.174 | 0.213 | −0.099 | 0.014 | −0.146 |
Escherichia coli | 0.162 | 0.046 | 0.025 | −0.146 | −0.037 | 0.013 | 0.116 | 0.194 |
Klebsiella spp. | −0.099 | −0.048 | −0.050 | 0.038 | −0.043 | 0.057 | −0.088 | −0.184 |
Proteus mirabilis | −0.080 | −0.069 | −0.053 | 0.064 | −0.036 | −0.051 | −0.153 | −0.062 |
Serratia marcescens | −0.076 | 0.025 | −0.063 | −0.372 | −0.221 | 0.074 | 0.144 | 0.172 |
Standardized differences could not be computed for variables with an asterisk “*” because neither the exposed nor unexposed groups in the specific quintile had patients with the specific variable.
Abbreviation: IPTW, inverse probability of treatment weighting.